{"id":"W2979625562","doi":"10.1182/blood.v120.21.3925.3925","title":"Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Bendamustine; Medicine; Tolerability; Lenalidomide; Regimen; Internal medicine; Chronic lymphocytic leukemia; Tumor lysis syndrome; Rituximab; Neutropenia; Phases of clinical research; Febrile neutropenia; Interim analysis; Clinical trial; Oncology; Pharmacology; Adverse effect; Leukemia; Chemotherapy; Lymphoma; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0107728,0.0009628733,0.001827747,0.0006669985,0.0005060261,0.002135108,0.00140505,0.001706941,0.006161784],"category_scores_gemma":[0.006262916,0.0005360104,0.002841947,0.0008720559,0.0004479798,0.00121951,0.0006837333,0.002727643,0.001700901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001378259,"about_ca_system_score_gemma":0.001620688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001800079,"about_ca_topic_score_gemma":0.003670955,"domain_scores_codex":[0.9968764,0.001832482,0.0002649392,0.0002834573,0.0004207607,0.0003219908],"domain_scores_gemma":[0.9904805,0.002831999,0.002996009,0.001086919,0.001115663,0.001488837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.771029,0.008171115,0.06943332,0.0009594817,0.006540905,0.0002667798,0.0001868886,0.003978011,0.0108438,0.0004275317,0.0326871,0.09547611],"study_design_scores_gemma":[0.3466899,0.2154156,0.3797389,0.0003234133,0.01146606,0.0007550399,0.0001599396,0.002912137,0.007913104,0.0007330817,0.03370792,0.0001849072],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8632659,0.009800356,0.002602407,0.002232784,0.0005878584,0.00435929,0.09377641,0.0005381716,0.02283688],"genre_scores_gemma":[0.8529339,0.001965547,0.005116241,0.003542266,0.0005049527,0.004355896,0.1237551,0.0002395852,0.007586497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0107728,"threshold_uncertainty_score":0.05697268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01843605526415957,"score_gpt":0.2763225775722773,"score_spread":0.2578865223081177,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}